See related letter by Lester *et al*., <http://arthritis-research.com/content/9/3/401> and related letter by Miceli-Richard *et al*., <http://arthritis-research.com/content/9/3/402>

Introduction
============

Polymorphisms in *CTLA-4*, the gene encoding cytotoxic T lymphocyte-associated antigen-4, have been widely studied in connection with genetic susceptibility to various autoimmune diseases \[[@B1]\], but studies have led to contradictory results in different populations.

Among *CTLA-4*gene polymorphisms, a G to A transition at position 49 (+49A/G) of exon 1 leads to an alanine to threonine amino acid substitution at codon 17 in the leader peptide (A17T), and a C to T transition at position 60 (CT60) is located within the 3\'-untranslated region \[[@B2]\]. The G allele of +49A/G has been associated with a predisposition to many autoimmune diseases (reviewed in \[[@B1]\]). Both polymorphisms are in linkage disequilibrium, which warrants haplotype analysis in studies of *CTLA-4*polymorphisms. The CT60 G allele has been reported to increase susceptibility to several autoimmune diseases \[[@B2]\], and a functional approach provided evidence for lower mRNA levels associated with the CT60 G allele \[[@B2]\].

Downie-Doyle and colleagues have recently reported a significant association of the *CTLA-4*+49A/G\*A allele and of the *CTLA-4*+49A/G\*A allele carrier haplotypes with primary Sjögren syndrome (pSS), especially in patients with anti-SSA or anti-SSB antibodies, in a study including 111 Australian patients with pSS and 156 controls \[[@B3]\].

The aim of our study was to investigate in a large case-control study whether *CTLA-4*CT60 and/or +49A/G SNPs were involved in genetic predisposition to pSS in French patients.

Materials and methods
=====================

Patients
--------

A first cohort of 142 unrelated patients with pSS diagnosed in accordance with the European American consensus group criteria \[[@B4]\] (37% without autoantibodies, 30% with anti-SSA antibodies only, and 33% with both anti-SSA and anti-SSB antibodies) and 241 healthy blood donors were genotyped for *CTLA-4*CT60 and +49A/G polymorphisms. A second independent cohort of 139 patients with pSS was further genotyped for *CTLA-4*+49A/G polymorphisms in a replication study. The geographical origin and the clinico-biological characteristics of the patients in this second cohort were the same as those in the first. In this second cohort, 27% of patients were anti-SSA and anti-SSB negative, 35% had anti-SSA only and 38% had both anti-SSA and anti-SSB. All patients and controls were Caucasians and provided informed consent.

Genotyping
----------

After the isolation of genomic DNA from peripheral blood mononuclear cells, *CTLA-4*CT60 and +49A/G polymorphisms were genotyped by restriction fragment length polymorphism with the use of *Bbv*I (+49A/G) and *Nla*III (CT60).

Statistical analysis
--------------------

Allelic and genotypic frequencies of *CTLA-4*CT60 and +49A/G polymorphisms were compared between patients and controls by using a two-sided χ^2^test. All genotyped SNPs were in Hardy--Weinberg equilibrium. *CTLA-4*(+49A/G or CT60) haplotypes, constructed with the PHASE program, were also examined for association with pSS. *P*\< 0.05 was considered significant.

Results
=======

In the first cohort of patients with pSS, the A allele of the *CTLA-4*+49A/G polymorphism was found on 73% of chromosomes in patients with pSS, in comparison with 66% in controls (*p*= 0.036, odds ratio (OR) 1.41, 95% confidence interval (CI) 1.02 to 1.95; Table [1](#T1){ref-type="table"}). No significant difference in *CTLA-4*+49A/G\*A allele frequencies was observed among subgroups of patients according to their anti-SSB and/or anti-SSA status (Table [1](#T1){ref-type="table"}). No difference in *CTLA-4*CT60 allelic or genotypic distribution was observed between patients (*n*= 142) and controls (*n*= 241). *CTLA-4*(+49A/G or CT60) haplotype distribution mirrored the *CTLA-4*+49A/G\*A allele excess among patients with pSS (A/A 48%, A/G 26%, G/G 26%, G/A 0.4%; in comparison with A/A 45%, A/G 21%, G/G 34% among controls), leading to an excess of +49A/G\*A allele carrier haplotypes among patients (*p*= 0.03, OR 1.41, 95% CI 1.02 to 1.95).

###### 

Allellic frequencies of *CTLA-4*49A/G polymorphism among patient controls

  *CTLA-4*+49A/G   Allele frequencies   *p*        Odds ratio (95% CI)                                                       
  ---------------- -------------------- ---------- --------------------- ---------- ---------- --------------------- ------- -------------------
  Cohort 1         *n*= 142             *n*= 47    *n*= 43               *n*= 90    *n*= 52                                  pSS vs controls
   A (Thr)         208 (73)             68 (72)    61 (71)               129 (72)   79 (76)    318 (66)              0.036   1.41 (1.02--1.95)
   G (Ala)         76 (27)              26 (28)    25 (29)               51 (28)    25 (24)    164 (34)              0.036   0.70 (0.51--0.98)
  Cohort 2         *n*= 139             *n*= 52    *n*= 49               *n*= 101   *n*= 38    Controls (*n*= 241)           
   A (Thr)         173 (62)             59 (57)    66 (67)               125 (62)   48 (63)    318 (66)              NS      0.85 (0.62--1.15)
   G (Ala)         105 (38)             45 (43)    32 (33)               77 (38)    28 (37)    164 (34)              NS      1.17 (0.86--1.60)
  Total            *n*= 281             *n*= 99    *n*= 92               *n*= 191   *n*= 90    Controls (*n*= 241)           
   A (Thr)         381 (68)             127 (64)   127 (69)              254 (66)   127 (71)   318 (66)              NS      1.08 (0.84--1.40)
   G (Ala)         181 (32)             71 (36)    57 (31)               128 (34)   53 (29)    164 (34)              NS      0.92 (0.71--1.19)

Numbers in parentheses are percentages. pSS, primary Sjögren syndrome; Ac+, presence of anti SSB and/or anti-SSA; Ac0, absence of anti-SSA or anti-SSB antibody; CI, confidence interval; NS, not significant.

To avoid the possibility of a false positive association of *CTLA-4*+49A/G\*A with pSS as a result of the somewhat small sample size of our first cohort, and because the *CTLA-4*+49A/G\*A allele has been only marginally associated with autoimmune diseases compared with the *CTLA-4*+49A/G\*G allele \[[@B1]\], we performed a replication study on a second independent cohort of 139 patients with pSS. In this second cohort, the *CTLA-4*+49A/G\*A allele was found on 62% of chromosomes in patients with pSS, compared with 66% in controls (*p*= 0.30; OR 0.85, 95% CI 0.63 to 1.16; Table [1](#T1){ref-type="table"}). Thus, the *CTLA-4*+49A/G\*A allele excess among patients with pSS from the first cohort was counterbalanced by its under-representation in the second cohort. When the results from the patients in both cohorts were pooled (*n*= 281), there was no difference in *CTLA-4*+49A/G polymorphism allelic or genotypic distribution in comparison with controls (*p*= 0.53, OR 1.09, 95% CI 0.84 to 1.4; Table [1](#T1){ref-type="table"}). The sex ratios among patients (0.97) and controls (0.06) were different. We therefore investigated *CTLA-4*+49A/G polymorphism genotypic distribution among males and females in the control group and found that it was not statistically different (*p*= 0.1), thus excluding any possible gender effect.

Our results therefore demonstrate a lack of association between *CTLA-4*CT60 or +49A/G polymorphisms and pSS among Caucasians.

Discussion
==========

The results from our first cohort were very close to those from the study of Downie-Doyle and colleagues \[[@B3]\], with a significant association of pSS with the +49A/G\*A allele and with the +49A/G\*A allele carriers haplotypes. The association observed in the first cohort, of two haplotypes bearing the same allele (*CTLA-4*+49A/G\*A), was actually more probably due to the statistical weight of the *CTLA-4*+49A/G\*A allele than to a true functional effect of two different haplotypes, bearing either *CTLA-4*CT60\*C or *CTLA-4*CT60\*T alleles, each having opposite functional effects on *CTLA-4*mRNA expression \[[@B2]\].

In fact, our results suggest a false positive association of *CTLA-4*+49A/G\*A allele with pSS in the first cohort of patients. When data were pooled (cohorts 1 and 2), no significant association was found with the *CTLA-4*+49A/G polymorphism in our Caucasian population of patients with pSS. This was not the consequence of different origin or different clinico-biological characteristics of the patients from the two cohorts and could only be the result of a sampling bias. Indeed, the findings observed in our first cohort of patients, as those from Downie-Doyle and colleagues \[[@B3]\], were unexpected because there are only rare examples of association of the *CTLA-4*A/G\*A allele with autoimmune diseases \[[@B5]-[@B7]\]. Consequently, we might have made premature conclusions if a replication study had not been performed.

Conclusion
==========

Our study illustrates the necessity to include a large number of patients in genetic case-control studies. In fact, sampling bias may partly account for some contradictory results previously reported for *CTLA-4*association studies in autoimmune diseases.
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